Back to Top

Annals of Oncology (AO)

Publisher :

Elsevier

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • Oncology
  • Medicine
e-ISSN :

1569-8041

Issue Frequency :

Monthly

Impact Factor :

50.5

p-ISSN :

0923-7534

Est. Year :

1990

Mobile :

31204853911

Country :

Netherlands The

Language :

English

APC :

YES

Impact Factor Assignee :

Google Scholar

Email :

annals1@esmo.org

Journal Descriptions

Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.


Annals of Oncology (AO) is :

International, Peer-Reviewed, Open Access, Refereed, Oncology, Medicine , Online or Print, Monthly Journal

UGC Approved, ISSN Approved: P-ISSN - 0923-7534, E-ISSN - 1569-8041, Established in - 1990, Impact Factor - 50.5

Not Provide Crossref DOI

Indexed in Scopus, PubMed

Not indexed in WoS, DOAJ, UGC CARE

Publications of AO

Research Article
  • dott image November, 2019

119P - Role of immune checkpoint inhibitors in bone sarcomas and future aspects

Background The most common subtypes of bone sarcomas are osteosarcoma and Ewing sarcoma. They are rare and heterogeneous form of cancers of mainly mesenchymal origin. Neo-adjuvant chemother...

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

Background Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA ...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile